Nalmexone
Chemical compound
- None
- (5α)-3,14-dihydroxy-17-(3-methyl-2-buten-1-yl)-4,5-epoxymorphinan-6-one
- 16676-26-9
16291-05-7 (HCl)
- 5360516
- 4514525
- AIB278UKIG
- DTXSID80168172
- Interactive image
- O=C4[C@@H]5Oc1c2c(ccc1O)C[C@H]3N(CC[C@]25[C@@]3(O)CC4)C\C=C(/C)C
InChI
- InChI=1S/C21H25NO4/c1-12(2)6-9-22-10-8-20-17-13-3-4-14(23)18(17)26-19(20)15(24)5-7-21(20,25)16(22)11-13/h3-4,6,16,19,23,25H,5,7-11H2,1-2H3/t16-,19+,20+,21-/m1/s1
- Key:OHKCLOQPSLQCQR-MBPVOVBZSA-N
Nalmexone (INN) (code names EN-1620A, UM-592), or nalmexone hydrochloride (USAN), is a semisynthetic, opioid partial agonist or mixed agonist-antagonist with both analgesic and narcotic antagonist properties that was never marketed.[1][2][3][4] In clinical studies it was found to have comparable analgesic efficacy to morphine, though with several-fold reduced potency.[5] In addition, nalmexone's side effects, the most common of which were sleepiness and sweating, were reported to be similar to those of morphine, albeit with a noticeably higher degree of incidence.[5]
Synthesis
See also
References
- ^ Macdonald F (1997). Dictionary of Pharmacological Agents. CRC Press. p. 1395. ISBN 978-0-412-46630-4. Retrieved 11 May 2012.
- ^ Casy AF, Parfitt RT (1986). Opioid Analgesics: Chemistry and Receptors. Springer. p. 55. ISBN 978-0-306-42130-3. Retrieved 11 May 2012.
- ^ Loew GH, Berkowitz DS (1978). "Quantum chemical studies of N-substituent variation in the oxymorphone series of opiate narcotics". Journal of Medicinal Chemistry. 21 (1): 101–106. doi:10.1021/jm00199a018. PMID 73588.
- ^ Forrest WH, Shroff PF, Mahler DL (1972). "Analgesic and other effects of nalmexone in man". Clinical Pharmacology and Therapeutics. 13 (4): 520–525. doi:10.1002/cpt1972134520. PMID 4557582. S2CID 30780581.
- ^ a b Committee on Problems of Drug Dependence (1969). Bulletin, problems of drug dependence. National Academies. p. 5873. NAP:10503. Retrieved 11 May 2012.
- v
- t
- e
modulators
Calcium blockers |
|
---|---|
Sodium blockers |
|
Potassium openers |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This analgesic-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e